MPZL2 and Parkinson disease: Although Mpzl2/Eva1 expression has not been studied extensively in the peripheral or central nervous system, except for studies on its role in hearing loss (Bademci et al., 2018; Wesdorp et al., 2018), upregulation of Mpzl2 expression has been reported in the substantia nigra (SN) in a MPTP mouse model of Parkinson’s disease (PD) using microarray analyses (Yeo et al., 2015).